|
CME
Background Information
To obtain credit, study the material and complete the CME Posttest
and Registration Form as instructed at the end of each activity.
Objective
After completing these educational activities, you should be
able to:
- formulate
a treatment plan based on the latest evidence-based treatment
options for patients with bipolar disorder
Statement
of Need and Purpose
Bipolar disorder remains challenging to diagnose and treat.
Even among patients who receive the correct diagnosis, many receive
inadequate treatment. Increased awareness of new pharmacotherapies
and the role of psychosocial management of bipolar disorder is imperative
to improve its treatment. These activities were designed to meet
the needs of participants in CME activities provided by the CME
Institute of Physicians Postgraduate Press, Inc. who have requested
information on the treatment of bipolar disorder. There are no prerequisites
for participating in these activities.
Accreditation
Statement
The CME Institute of Physicians Postgraduate Press, Inc. is
accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
Credit
Designation
The CME Institute of Physicians Postgraduate Press, Inc. designates
each of these educational activities for up to 0.25 Category 1 credit
toward the AMA Physician’s Recognition Award. Each participant
should claim only those credits that he/she actually spent in the
educational activity.
Date
of Original Release/Review
These Brief Reports were published in June and July 2005 and
are eligible for CME credit through July 31, 2007. The latest review
of this material was June 2005.
Faculty
Disclosure
In the spirit of full disclosure and in compliance with all ACCME
Essential Areas and Policies, the faculty for this CME activity
were asked to complete a statement regarding all relevant personal
financial relationships between themselves or their spouse/partner
and any commercial interest, (i.e., a proprietary entity producing
health care goods or services) occurring within the 12 months prior
to joining this activity. The CME Institute has resolved any conflicts
of interest that were identified. The disclosures are as follows:
Dr. Bowden [see
disclosure]
Dr. Ketter [see
disclosure]
Dr. Sachs [see
disclosure]
Dr. Thase [see
disclosure]
Disclosure
of Off-Label Usage
In these Brief Reports, investigational information about pharmaceutical
agents may be presented that is outside U.S. Food and Drug Administration-approved
labeling. This information is intended solely as continuing medical
education and is not intended to promote off-label use of any of
these medications. Please consult the paragraph titled "Disclosure
of Off-Label Usage" at the end of each Brief Report for a complete
listing of off-label or investigational uses. If you have questions,
contact the medical affairs department of the manufacturer for the
most recent prescribing information.
Review
Process
These activities have undergone a 3-tier review process: (1) the
entire faculty discussed the content at a peer-review planning session;
(2) the Chair reviewed each activity for accuracy and fair balance;
and (3) a member of the External CME Advisory Board reviewed the
activities to determine whether the material is evidence-based and
objective.
Acknowledgment
These Brief Reports are developed from the teleconference "The
Journal of Clinical Psychiatry Current Reports: Focus on Bipolar
Disorder Treatment," which was held May 2, 2005, and was independently
developed by the CME Institute of Physicians Postgraduate Press,
Inc. pursuant to an educational grant from GlaxoSmithKline. The
opinions expressed herein are those of the faculty and do not necessarily
reflect the opinions of the CME provider and publisher or the commercial
supporter.
|
